ILMN vs RXRX: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

ILMN is the larger of the two ($32.61B market cap): the incumbent the market prices for continued execution (34.88x forward earnings, beta 1.45). RXRX is the smaller challenger ($2.23B), priced similarly on forward earnings (-4.33x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.

ILMN vs RXRX: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricILMNRXRXWhat it tells you
Market cap$32.61B$2.23BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E34.88-4.33Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta1.451.15Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range52% of range33% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book10.422.21How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how ILMN and RXRX affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ILMN and RXRX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ILMN and RXRX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Illumina (ILMN) do?

Illumina designs, makes, and sells next-generation DNA sequencing systems and the consumables that run on them, serving research, clinical, and applied-genomics customers. Its business follows a razor-and-blades model: instruments such as the high-throughput NovaSeq X, the NextSeq, and the benchtop MiSeq seed an installed base, and the bulk of revenue then comes from recurring sequencing consumables (reagents and flow cells), which historically make up the majority of sales. The company is also pushing into multiomics, proteomics, and clinical diagnostics to expand what its platforms can measure. Illumina is headquartered in San Diego, was founded in 1998, and is led by CEO Jacob Thaysen.

Full ILMN guide

What does Recursion Pharmaceuticals (RXRX) do?

Recursion Pharmaceuticals is a Salt Lake City-based, clinical-stage technology-enabled biopharmaceutical company that aims to industrialize drug discovery. Its platform combines automated wet-lab biology, high-throughput cellular imaging that generates petabytes of proprietary experimental data, and machine-learning models that map relationships between genes, compounds, and disease, layered with Exscientia's automated precision molecular design. Recursion intends to make money three ways: partnership and collaboration payments (upfront fees, research funding, and milestone payments from large pharma companies that use its platform), future royalties on any partnered drugs that reach market, and value from its own wholly owned pipeline of clinical candidates. Today the company is pre-revenue in the product sense: reported revenue is small (roughly $6.5 million in Q1 2026 and $7.7 million in Q2 2026) and comes mostly from partnerships rather than drug sales.

Full RXRX guide

ILMN vs RXRX: how do they differ?

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

  • ILMN drivers: Installed base and the consumables annuity; The NovaSeq X transition.
  • RXRX drivers: An industrial-scale AI platform and proprietary data moat; A deep big-pharma partnership book.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Competition is intensifying: Ultima Genomics markets bulk whole-genome sequencing near $80 a genome, Element Biosciences' AVITI undercuts benchtop economics, and PacBio and Oxford Nanopore hold long-read niches, all pressuring Illumina's pricing and share. For RXRX, the central risk is that Recursion has no approved drug and remains deeply unprofitable, posting a net loss of roughly $131 million in Q2 2026 against only about $7.7 million of revenue, and about $519 million over the trailing twelve months, so the entire valuation rests on platform promise rather than proven output.

ILMN or RXRX: which should you pick?

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ILMN if you believe its drivers more; RXRX if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ILMN and RXRX guides.

ILMN vs RXRX: the full fundamentals

ILMN. Illumina's multiple has expanded far faster than its earnings: the shares are up about 94% year to date and 172% over a year, while consensus calls for 2026 revenue growth near 11% and EPS of about $5.36. At roughly 43 times forward earnings and 36 times EV/EBITDA, the price assumes growth and margin expansion continue well beyond 2026, and the stock sits above the $241 average analyst target even as individual targets, such as JPMorgan's move to $320, have risen.

RXRX. Because Recursion is pre-profit with minimal revenue, traditional earnings multiples do not apply, and the figures that matter most are cash on hand, the rate of cash burn, and how long the runway lasts before the company must raise money again. The October 2026 offering pushed the stated runway into 2029 at the cost of about 61.5 million new shares, while REC-4881 data and the Sanofi option added evidence on the pipeline side. Valuation is still a bet on future platform output and partnership milestones rather than on current financial performance, and Q3 2026 results are expected around November 4.

Headline figures (approximate, October 2026): ILMN shows revenue (ttm) ~$4.49 billion; Q2 2026 revenue ~$1.16 billion, up ~9% year over year, 2026 revenue consensus ~$4.62 billion (~11% growth); 2027 consensus ~$4.92 billion, margins (ttm) Gross ~68%, operating ~21%, net ~18%, net income and eps (ttm) ~$824 million net income; EPS ~$5.39 trailing, ~$6.12 forward; RXRX shows revenue (q2 2026) ~$7.7 million (TTM ~$55 million, mostly partnership and milestone revenue), net loss (q2 2026) ~$131 million (TTM ~$519 million); EPS -$0.25 vs -$0.23 expected, cash ~$561 million on September 30, 2026 (preliminary), before ~$200 million of offering proceeds, stated cash runway Into 2029, including net proceeds of the October 2026 offering.

The bottom line: ILMN vs RXRX

ILMN and RXRX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ILMN and RXRX exposure against your real portfolio. It is not an investment adviser.

Wondering how ILMN or RXRX fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Illumina

Ask Walnut's AI anything about ILMN and see how it fits what you own.

FAQ

What is the difference between ILMN and RXRX?

+

Illumina designs, makes, and sells next-generation DNA sequencing systems and the consumables that run on them, serving research, clinical, and applied-genomics customers. Recursion Pharmaceuticals is a Salt Lake City-based, clinical-stage technology-enabled biopharmaceutical company that aims to industrialize drug discovery. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is ILMN or RXRX the better stock?

+

Neither is universally better. ILMN is the larger incumbent; RXRX is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, ILMN or RXRX?

+

On forward P/E (as of November 2026), ILMN trades at 34.88x and RXRX at -4.33x, so RXRX is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both ILMN and RXRX?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of ILMN vs RXRX?

+

ILMN: Competition is intensifying: Ultima Genomics markets bulk whole-genome sequencing near $80 a genome, Element Biosciences' AVITI undercuts benchtop economics, and PacBio and Oxford Nanopore hold long-read niches, all pressuring Illumina's pricing and share. The underlying sequencing market is growing slowly, and soft academic and research funding, including pressure on US research budgets, can delay instrument purchases. China is now only about 3% of revenue after Illumina was effectively shut out of that market, where domestic players BGI and MGI dominate. Tariffs and a relatively high valuation add further risk. Valuation is now a larger part of the risk: at about 48 times trailing earnings and roughly 8.8 times sales after a 94% gain in 2026, the stock trades above the average analyst target of about $241, and the consensus for the third quarter calls for EPS of about $1.36 on revenue of about $1.15 billion, roughly 1% growth. A recall listing for the NovaSeq 6000Dx server correction is a reminder that clinical instruments carry regulatory exposure. RXRX: The central risk is that Recursion has no approved drug and remains deeply unprofitable, posting a net loss of roughly $131 million in Q2 2026 against only about $7.7 million of revenue, and about $519 million over the trailing twelve months, so the entire valuation rests on platform promise rather than proven output. AI-driven drug discovery as a category is still unproven at the finish line, and skeptics note that no AI-originated compound has yet delivered a blockbuster approval, leaving open the possibility that the platform advantage does not translate into clinical success. Early data such as the REC-4881 and REC-1245 results come from small, open-label studies, and Recursion's candidates could still fail in larger trials like most clinical-stage biotech assets do; even partnered programs depend on decisions outside Recursion's control. Dilution is not hypothetical: the October 2026 offering added about 61.5 million shares at $3.25, and although the company now guides to a cash runway into 2029, continued losses mean it may need to raise capital again. The stock has also been volatile, down about 42% over the past year and trading well below its 52-week high of about $7.18.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ILMN or RXRX; figures are approximate and dated (as of November 2026). Verify current data before investing.